Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20148877 | 0.79 | AR (0.39) | CNR2HSD17B10HIF1AEPAS1 | |
| SCHEMBL20141268 | 0.78 | HIF1A (0.38) | CNR2HSD17B10HIF1AEPAS1 | |
| SCHEMBL20148884 | 0.78 | HIF1A (0.38) | CNR2HSD17B10HIF1AEPAS1 | |
| SCHEMBL21564211 | 0.73 | AR (0.38) | CNR2HIF1AEPAS1 | |
| SCHEMBL20141064 | 0.69 | PDE10A (0.30) | — | |
| SCHEMBL14777105 | 0.68 | CNR2 (0.34) | CNR2 | |
| SCHEMBL20139673 | 0.68 | AR (0.34) | — | |
| SCHEMBL20140382 | 0.67 | MAPK1 (0.44) | CNR2HIF1A | |
| SCHEMBL20148889 | 0.66 | AR (0.35) | HSD17B10 | |
| SCHEMBL19922669 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| WO-2018111795-A2 | USE OF SGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | CNR2 1255/4885HSD17B10 2294/4885HIF1A 1126/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | CNR2 1268/4885HSD17B10 2420/4885HIF1A 1023/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | CNR2 1255/4885HSD17B10 2294/4885HIF1A 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.